Evaluating the feasibility of lantibiotics as an alternative therapy against bacterial infections in humans

Bibliography

• Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol R 2010;74(3):417-33
   PubMed Web of Science ®Google Scholar
• Lubelski J, Rink R, Khusainov R, Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. Cell Mol Life Sci 2008;65(3):455-76
   PubMed Web of Science ®Google Scholar
• Willey JM, Van der Donk WA. Lantibiotics: peptides of diverse structure and function. Annu Rev Microbiol 2007;61:477-501
   PubMed Web of Science ®Google Scholar
• Hasper HE, Kramer NE, Smith JL, An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 2006;313(5793):1636-7
   PubMed Web of Science ®Google Scholar
• Maher S, Vilk G, Kelleher F, Chemical modification of the carboxyl terminal of nisin A with biotin does not abolish antimicrobial activity against the indicator organism, Kocuria rhizophila. Int J Pept Res Ther 2009;15(3):219-26
   Web of Science ®Google Scholar
• Rollema HS, Kuipers OP, Both P, Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl Environ Microbiol 1995;61(8):2873-8
   PubMed Web of Science ®Google Scholar
• Rollema HS, Metzger JW, Both P, Structure and biological activity of chemically modified nisin A species. Eur J Biochem 1996;241(3):716-22
   PubMedGoogle Scholar
• Field D, Quigley L, O'Connor PM, Studies with bioengineered Nisin peptides highlight the broad?spectrum potency of Nisin V. Microb Biotechnol 2010;3(4):473-86
   PubMed Web of Science ®Google Scholar
• Castiglione F, Lazzarini A, Carrano L, Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chem Biol 2008;15(1):22-31
   PubMed Web of Science ®Google Scholar
• Mantovani HC, Russell JB. Nisin resistance of Streptococcus bovis. Appl Environ Microbiol 2001;67(2):808-13
   PubMed Web of Science ®Google Scholar
• Ghobrial OG, Derendorf H, Hillman JD. Pharmacodynamic activity of the lantibiotic MU1140. Int J Antimicrob Agents 2009;33(1):70-4
   PubMed Web of Science ®Google Scholar
• Collins B, Curtis N, Cotter PD, The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics. Antimicrob Agents Chemother 2010;54(10):4416
   PubMed Web of Science ®Google Scholar
• Fernandez L, Delgado S, Herrero H, The bacteriocin nisin, an effective agent for the treatment of staphylococcal mastitis during lactation. J Hum Lact 2008;24(3):311-16
   PubMed Web of Science ®Google Scholar
• Velasquez JE, van der Donk WA. Genome mining for ribosomally synthesized natural products. Curr Opin Chem Biol 2010;15(1):1-11
   Web of Science ®Google Scholar
• de Jong A, van Heel AJ, Kok J, Kuipers OP. BAGEL2: mining for bacteriocins in genomic data. Nucleic Acids Res 2010;38(Suppl 2):W647-51
   PubMed Web of Science ®Google Scholar
• Ugurlu T, Turkoglu M, Gurer US, Akarsu BG. Colonic delivery of compression coated nisin tablets using pectin/HPMC polymer mixture. Eur J Pharm Biopharm 2007;67(1):202-10
   PubMed Web of Science ®Google Scholar
• Ghobrial O, Derendorf H, Hillman JD. Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J Pharm Sci 2010;99(5):2521-8
   PubMed Web of Science ®Google Scholar
• Rickert DE, Dingley K, Ubick E, Determination of the tissue distribution and excretion by accelerator mass spectrometry of the nonadecapeptide 14C-Moli1901 in beagle dogs after intratracheal instillation. Chem Biol Interact 2005;155(1-2):55-61
   PubMed Web of Science ®Google Scholar
• Grasemann H, Stehling F, Brunar H, Inhalation of moli1901 in patients with cystic fibrosis. Chest 2007;131(5):1461-6
   PubMed Web of Science ®Google Scholar
• Ghobrial OG, Derendorf H, Hillman JD. Development and validation of a LC-MS quantification method for the lantibiotic MU1140 in rat plasma. J Pharm Biomed Anal 2009;49(4):970-5
   PubMed Web of Science ®Google Scholar
• Ghobrial O, Derendorf H, Hillman JD. Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140. Eur J Pharm Sci 2010;41(5):658-64
   PubMed Web of Science ®Google Scholar
• McNulty MJ, Hutabarat RH, Findlay JWA, Pharmacokinetics and tissue distribution of the nonadecapeptide Moli1901 in rats and mice. Xenobiotica 2003;33(2):197-210
   PubMed Web of Science ®Google Scholar
• Steiner I, Errhalt P, Kubesch K, Pulmonary pharmacokinetics and safety of nebulized duramycin in healthy male volunteers. Naunyn Schmiedebergs Arch Pharmacol 2008;378(3):323-33
   PubMed Web of Science ®Google Scholar
• Aranha CC, Gupta SM, Reddy KVR. Assessment of cervicovaginal cytokine levels following exposure to microbicide Nisin gel in rabbits. Cytokine 2008;43(1):63-70
   PubMed Web of Science ®Google Scholar
• Maher S, McClean S. Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro. Biochem Pharmacol 2006;71(9):1289-98
   PubMed Web of Science ®Google Scholar
• Hagiwara A, Imai N, Nakashima H, A 90-day oral toxicity study of nisin A, an anti-microbial peptide derived from Lactococcus lactis subsp. lactis, in F344 rats. Food Chem Toxicol 2010;48(8-9):2421-8
   PubMed Web of Science ®Google Scholar
• Gupta SM, Aranha CC, Reddy KVR. Evaluation of developmental toxicity of microbicide Nisin in rats. Food Chem Toxicol 2008;46(2):598-603
   PubMed Web of Science ®Google Scholar
• Cox CR, Coburn PS, Gilmore MS. Enterococcal cytolysin: a novel two component peptide system that serves as a bacterial defense against eukaryotic and prokaryotic cells. Curr Protein Pept Sc 2005;6(1):77-84
   PubMed Web of Science ®Google Scholar
• Huang T, Geng H, Miyyapuram VR, Isolation of a variant of subtilosin A with hemolytic activity. J Bacteriol 2009;191(18):5690-6
   PubMed Web of Science ®Google Scholar
• Aranha C, Gupta S, Reddy KVR. Contraceptive efficacy of antimicrobial peptide Nisin: in vitro and in vivo studies. Contraception 2004;69(4):333-8
   PubMed Web of Science ®Google Scholar
• Reddy KVR, Aranha C, Gupta SM, Yedery RD. Evaluation of antimicrobial peptide nisin as a safe vaginal contraceptive agent in rabbits: in vitro and in vivo studies. Reproduction 2004;128(1):117-26
   PubMed Web of Science ®Google Scholar
• Gupta SM, Aranha CC, Bellare JR, Reddy KVR. Interaction of contraceptive antimicrobial peptide nisin with target cell membranes: implications for use as vaginal microbicide. Contraception 2009;80(3):299-307
   PubMed Web of Science ®Google Scholar
• De Kwaadsteniet M, Doeschate KT, Dicks LMT. Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus. Lett Appl Microbiol 2009;48(1):65-70
   PubMed Web of Science ®Google Scholar
• Zeitlin PL, Boyle MP, Guggino WB, Molina L. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2004;125(1):143-9
   PubMed Web of Science ®Google Scholar
• Schmidt S, Schuck E, Kumar V, Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents–minimum inhibitory concentration versus time-kill curves. Expert Opin Drug Dis 2007;2(6):849-60
   PubMed Web of Science ®Google Scholar
• Lee MD. Antibiotics from microbispora. US6551591B1; 2003
   Google Scholar
• Walsh SM, Shah AG, Mond JJ. Topical anti-infective formulations. 10/733,046; 2003
   Google Scholar
• Mota-Meira M, Lapointe G, Lacroix C, Lavoie MC. MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against bacterial pathogens. Antimicrob Agents Chemother 2000;44(1):24-9
   PubMed Web of Science ®Google Scholar
• Wadman SN, Dawson MJ, Bargallo C. Use of type-B lantibiotic-based compounds having antimicrobial activity. 20090203583; 2009
   Google Scholar
• Tagg JR, Chilcott CN, Burton JP. Treatment of malodour. US7595041B2; 2009
   Google Scholar
• Margolis D, Bowe W. Bacterial-derived BLIS for treatment of acne. 12/086,335; 2006
   Google Scholar
• Dawson MJ, Bargallo JC, Appleyard AN, F3W variants of the lantibiotic mersacidin and its use. 7592308; 2009
   Google Scholar
• Blackburn P, de la Harpe J. Moist bacteriocin disinfectant wipes and methods of using the same. US8/479280(US5762948); 1998
   Google Scholar
• Blackburn P, Polak J, Gusik SA, Rubino SD. Bacteriocin compositions comprising lanthionine containing bacteriocins and non-bactericidal agents. Nisin compositions for use as enhanced, broad range bactericides. 5135910; 1993
   Google Scholar
• Hillman JD. Replacement therapy for dental caries. US5607672; 1997
   Google Scholar